scholarly journals High RNA-binding Motif Protein 3 Expression Is Associated with Improved Clinical Outcomes in Invasive Breast Cancer

2018 ◽  
Vol 21 (3) ◽  
pp. 288 ◽  
Author(s):  
Sun Hee Kang ◽  
Jihyoung Cho ◽  
Hasong Jeong ◽  
Sun Young Kwon
Keyword(s):  
Breast Cancer ◽  
Clinical Outcomes ◽  
Invasive Breast Cancer ◽  
Rna Binding ◽  
Binding Motif

scholarly journals High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer

BMC Cancer ◽  
2013 ◽  
Vol 13 (1) ◽  
Author(s):  
Emman Shubbar ◽  
Khalil Helou ◽  
Anikó Kovács ◽  
Szilárd Nemes ◽  
Shahin Hajizadeh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Outcomes ◽  
Invasive Breast Cancer ◽  
Poor Prognosis

Evaluation of invasive breast cancer using a 12-chemokine gene expression score (CS): Correlation with clinical outcomes.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 11050-11050
Author(s):  
Sangeetha Prabhakaran ◽  
Victoria T. Rizk ◽  
William J. Fulp ◽  
Anders E. Berglund ◽  
James J Mule' ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Clinical Outcomes ◽  
Invasive Breast Cancer ◽  
Chemokine Gene ◽  
Expression Score ◽  
Gene Expression Score ◽  
Chemokine Gene Expression

scholarly journals Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer

eLife ◽  
2014 ◽  
Vol 3 ◽  
Author(s):  
Sakari Vanharanta ◽  
Christina B Marney ◽  
Weiping Shu ◽  
Manuel Valiente ◽  
Yilong Zou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Progression ◽  
Rna Binding ◽  
Binding Protein ◽  
Rna Binding Protein ◽  
Wnt Signaling Pathway ◽  
Experimental Models ◽  
Breast Cancer Progression ◽  
Binding Motif ◽  
Clinical Breast

The mechanisms through which cancer cells lock in altered transcriptional programs in support of metastasis remain largely unknown. Through integrative analysis of clinical breast cancer gene expression datasets, cell line models of breast cancer progression, and mutation data from cancer genome resequencing studies, we identified RNA binding motif protein 47 (RBM47) as a suppressor of breast cancer progression and metastasis. RBM47 inhibited breast cancer re-initiation and growth in experimental models. Transcriptome-wide HITS-CLIP analysis revealed widespread RBM47 binding to mRNAs, most prominently in introns and 3′UTRs. RBM47 altered splicing and abundance of a subset of its target mRNAs. Some of the mRNAs stabilized by RBM47, as exemplified by dickkopf WNT signaling pathway inhibitor 1, inhibit tumor progression downstream of RBM47. Our work identifies RBM47 as an RNA-binding protein that can suppress breast cancer progression and demonstrates how the inactivation of a broadly targeted RNA chaperone enables selection of a pro-metastatic state.

scholarly journals RBMS3 is differentially expressed in both lymph node and brain metastases in human breast cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Brain Metastases ◽  
Rna Binding ◽  
Metastatic Breast ◽  
Metastatic Tumor ◽  
Clinical Problem ◽  
Binding Motif ◽  
Primary Tumors ◽  
The Brain

Metastasis to the brain is a clinical problem in patients with breast cancer (1-3). We mined published microarray data (4, 5) to compare primary and metastatic tumor transcriptomes for the discovery of genes associated with brain metastasis in humans with metastatic breast cancer. We found that RNA binding motif single stranded interacting protein 3, encoded by RBMS3, was among the genes whose expression was most quantitatively different in the brain metastases of patients with metastatic breast cancer. RBMS3 mRNA was present at decreased quantities in brain metastatic tissues as compared to primary tumors of the breast. Importantly, expression of RBMS3 in primary tumors was significantly correlated with patient recurrence-free survival in patients with breast cancer. Modulation of RBMS3 expression may be relevant to the biology by which tumor cells metastasize from the breast to the brain.

Clinical outcomes of estrogen receptor (ER)-negative and progesterone receptor (PgR)-positive invasive breast cancer.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 567-567
Author(s):  
Melissa Chan ◽  
Martin Chang ◽  
Rosa Gonzalez ◽  
Belinda Lategan ◽  
Elvira del Barco ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Progesterone Receptor ◽  
Clinical Outcomes ◽  
Invasive Breast Cancer

Relationship of the breast ductal carcinoma in situ (DCIS) immune microenvironment with clinicopathological features: An institutional experience.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e12565-e12565
Author(s):  
Lauren Eisenbud ◽  
Tsering G. Lama Tamang ◽  
Caleb Cheng ◽  
Ibe Ifegwu ◽  
Tianyi Tang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Clinical Outcomes ◽  
Invasive Ductal Carcinoma ◽  
Invasive Breast Cancer ◽  
Ductal Carcinoma ◽  
Recurrent Disease ◽  
Response To Therapy ◽  
Data Set ◽  
Risk Of Recurrence

e12565 Background: DCIS is usually treated with resection followed by 5 years of adjuvant endocrine therapy for hormone receptor (HR) + DCIS. Endocrine therapy is not used in HR- DCIS. Although DCIS is considered a precursor lesion to invasive breast cancer, the different molecular subtypes confer variable clinical outcomes. The host immune response plays a key role in breast cancer progression and response to therapy. However, relative to invasive breast cancer, the immune milieu of DCIS is less understood. This retrospective study compares the clinical outcomes and tumor microenvironment of HR+ and HR- DCIS in order to identify clinical and immunological features in HR- DCIS that may predict an increased risk of recurrence or progression to invasive breast cancer. Methods: A single institution retrospective chart review was performed to identify patients diagnosed with DCIS between 2012 and 2017. A clinico-pathologic data set, as well as the PD-L1 expression of the DCIS and TILs were collected and correlated with various outcomes. Results: Our cohort consisted of 20 cases of HR- DCIS and 50 cases of HR+ DCIS. Overall, 56% were Caucasian, 20% Asian, 18% Hispanic, and 6% African American. Of the HR- patients, 70% were Caucasian, 15% Hispanic, and 15% Asian. Of the 17 HR- patients with available HER2 data, 76% had HER2+, and 24% triple negative (TN) DCIS. 18% of the HR+ patients and 38% of the HR- patients were PD-L1+. 25% of the HR-/HER2+ patients, and 75% of the TN patients were PD-L1+. 6% of the HR+ patients developed recurrent disease, 2 with DCIS and 1 with invasive ductal carcinoma. 20% of the HR- patients had recurrent disease, all of whom were HER2+. Of the HR- patients that recurred, 2 recurred with metastatic disease, 1 with ipsilateral invasive ductal carcinoma, and 1 with DCIS. All 7 patients that recurred had original DCIS pathology showing a high nuclear grade. Our future results at the time of the meeting will expand on this cohort. Conclusions: This retrospective analysis showed that HR- DCIS conferred higher rates of local and distant recurrence. Therefore, there is a need for treatments to reduce the recurrence rates of HR- DCIS. There are ongoing clinical trials for the high risk, HR-/HER2+ DCIS subtype. TN DCIS is also an aggressive phenotype. Given the high rate of PD-L1 positivity we detected in TN DCIS, immune-based therapy may be useful in the adjuvant setting to reduce the risk of recurrence in this cohort of patients.

Sign in / Sign up

Export Citation Format

Share Document